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Abstract 
Background: Several studies have reported high efficacy and safety of artemisinin‑based combination therapy (ACT) 
mostly under strict supervision of drug intake and limited to children less than 5 years of age. Patients over 5 years 
of age are usually not involved in such studies. Thus, the findings do not fully reflect the reality in the field. This study 
aimed to assess the effectiveness and safety of ACT in routine treatment of uncomplicated malaria among patients of 
all age groups in Nanoro, Burkina Faso.
Methods: A randomized open label trial comparing artesunate–amodiaquine (ASAQ) and artemether–lumefantrine (AL) 
was carried out from September 2010 to October 2012 at two primary health centres (Nanoro and Nazoanga) of Nanoro 
health district. A total of 680 patients were randomized to receive either ASAQ or AL without any distinction by age. Drug 
intake was not supervised as pertains in routine practice in the field. Patients or their parents/guardians were advised on the 
time and mode of administration for the 3 days treatment unobserved at home. Follow‑up visits were performed on days 3, 7, 
14, 21, and 28 to evaluate clinical and parasitological resolution of their malaria episode as well as adverse events. PCR geno‑
typing of merozoite surface proteins 1 and 2 (msp‑1, msp‑2) was used to differentiate recrudescence and new infection.
Results: By day 28, the PCR corrected adequate clinical and parasitological response was 84.1 and 77.8 % respectively 
for ASAQ and AL. The cure rate was higher in older patients than in children under 5 years old. The risk of re‑infection 
by day 28 was higher in AL treated patients compared with those receiving ASAQ (p < 0.00001). Both AL and ASAQ 
treatments were well tolerated.
Conclusion: This study shows a lowering of the efficacy when drug intake is not directly supervised. This is worrying 
as both rates are lower than the critical threshold of 90 % required by the WHO to recommend the use of an anti‑
malarial drug in a treatment policy.
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Background
Malaria remains the main cause of morbidity and mor-
tality in Burkina Faso. Based on the recommendation of 
the World Health Organization, artemisinin-based com-
bination therapy (ACT) was adopted by the national 
malaria control programme (NMCP) for the treatment 
of uncomplicated malaria since 2005. The two combi-
nations adopted in the country as first-line regimen are 
artemether–lumefantrine (AL) and artesunate–amodi-
aquine (ASAQ) [1, 2]. Globally, several efficacy and effec-
tiveness studies have demonstrated their high efficacy 
and safety for the treatment of uncomplicated Plasmo-
dium falciparum malaria [3–5].
However, in most of these studies, drug intake was 
supervised by a study team and treatment was strictly 
administered in accordance with manufacturer’s rec-
ommendations. Yet, in poor resource settings with high 
malaria morbidity, strict adherence to these conditions 
is often not observed in real life settings. A recent study 
conducted in this study area has already shown a low-
ering of the cure rate of ACT in real life comparative to 
the other efficacy studies [6]. In addition, most of those 
studies were limited to children under five and the older 
populations are typically not involved. Despite the upheld 
notion that adults are immune-protected, behaviour 
towards the treatment, such as not completing treat-
ment regiments, could be higher in adults and this could 
negatively influence treatment outcomes. Therefore, 
an assessment of treatment outcomes that would fully 
reflects the reality in the field has to involve all age groups 
in the population. Moreover, the best indicator for safety 
could be obtained from adults since children are chal-
lenged to make recalls on safety information. It is based 
on these compelling reasons that this study was carried 
out in order to assess the effectiveness and safety of the 
two recommended forms of ACT in Burkina Faso as they 
are used routinely in treating uncomplicated malaria in 
all age groups in the country.
Methods
Study area
The study was carried out from September 2010 to Octo-
ber 2012 at two primary health centers (Nanoro and 
Nazoanga) of Nanoro health district (NHD) in Burkina 
Faso. Nanoro is situated at about 85  km from Ouaga-
dougou, the capital city of the country. It is classified as 
hyperendemic and malaria transmission is seasonal with 
a peak at rainy season that lasts usually from June–July 
to October–November [7]. The entomological inocula-
tion rate is estimated at 50–60 infective bites/person/
year and the commonest vectors are Anopheles gambiae, 
Anopheles funestus and Anopheles arabiensis (A. Diabate, 
personal communication). Plasmodium falciparum is the 
most prevalent malaria parasite. The predominant ethnic 
group is Mossi, minorities are Gourounsi and Fulani. The 
majority of the population practice subsistence farming 
[8].
Study participants and inclusion criteria
Patients presenting at the two health facilities with 
symptoms or signs suggestive of malaria were reviewed 
by study nurses without any age distinction. The inclu-
sion criteria were: (a) fever or history of fever within the 
previous 24 h, (b) mono infection with P. falciparum, (c) 
parasites density comprised between 2000 and 200,000 
asexual forms per microlitre of blood, (d) haemoglobin 
>5  g/dL. Patients were excluded from the study if they 
presented (a) danger signs (unable to drink or breast-
feed; vomiting more than twice in 24 h; recent history of 
convulsions; unconsciousness or unable to sit or stand), 
(b) severe malaria, (c) severe malnutrition (defined as 
weight for height <70 % of the median NCHS/WHO ref-
erence), (d) a documented history of adequate malaria 
treatment in the preceding 2 weeks, (e) any evidence of 
chronic disease or of a concurrent non-malarial febrile 
illness, (f ) history of serious side effects with the study 
drugs, (g) a reported pregnancy for child bearing age 
women and patient or his parent/guardians unwilling-
ness to participate.
Study procedures
Patients were randomly assigned to receive either AL 
(Coartem®, Novartis) or ASAQ (Winthrop, sanofi 
aventis). A computer-generated randomization list 
provided by the site quality assurance manager was 
used for treatment allocation. Treatment was admin-
istered according to the national algorithm for 
malaria cases management and was strictly adhered 
to. In ASAQ group, treatment was administered once 
daily, at the standard dose as follows: 4.5 to <9  kg, 1 
tablet 25/67.5  mg; 9 to <18  kg, 1 tablet 50/135  mg; 
18 to <36  kg, 1 tablet 100/270  mg; ≥36  kg, 2 tablets 
100/270  mg. In AL group, treatment was given twice 
daily according to the body weight as follows: 5–14 kg, 
one tablet per dose; 15–24  kg, two tablets per dose; 
25–34 kg, three tablets per dose and adult, four tablets 
Trial registration: NCT01232530
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per dose. Patients (adults) or their parents/guard-
ians (children) were advised of the time and mode of 
administration for the 3 days treatment taken at home 
unobserved. Patients and or their parents/guardians 
were advised to administer AL with fat containing 
food and were asked to come back (with their child) 
for scheduled visits on days 3, 7, 14, 21, and 28, or if 
the participant was sick between visits (unscheduled 
visit). At each visit a physical examination was per-
formed. Blood sample was taken from the finger to 
prepare thick/thin film, photometric measurement of 
haemoglobin (HemoCue® 301+) and spotted onto fil-
ter paper (Whatman 3MM, Maidstone, UK) for later 
molecular analysis. For identification and reporting 
of AEs, patients were assessed at each visit accord-
ing to a standardized checklist and the information 
was recorded on the case record form (CRF). A sever-
ity grading scale, based on the toxicity grading scales 
developed by the WHO was used to grade severity of 
all reported adverse events (AEs) and clinical exami-
nation findings. All AEs were catalogued based on 
their frequency, severity, and relationship with AL and 
ASAQ treatment [9].
Microscopic examination
Blood smears were read in the field at each health facil-
ity by light microscopy after they have been stained with 
3 % Giemsa for 30 min. Parasite density was determined 
by counting the number of asexual parasites per 200 
white blood cells, and calculated per micro liter of blood 
by assuming the white blood cells at 8000/µL. A smear 
was declared negative when the examination of 100 
thick-film fields did not reveal the presence of asexual 
parasites. Blood smears were examined by two readers 
and, in the case of discordant results, by a third reader. 
Discordant results were defined as a difference between 
the two readers in (a) Plasmodium species, (b) positive 
and negative, (c) with parasite >400/µL; if the higher 
count divided by the lower count was >2, (d) with para-
site ≤400/µL; if the higher reading is >Log10 higher than 
the lower reading.
Parasite genotyping
Molecular analysis was performed at the Molecular 
Biology laboratory of Centre Muraz of Bobo-Dioul-
asso, Burkina Faso. Dried blood spots from day 0 (pre-
treatment) and from day of recurrent parasitaemia 
(post-treatment) during the 28  days follow-up were 
used for parasite genotyping. Plasmodium falcipa-
rum DNA was extracted from dried blood spots using 
QIamp DNA miniKit (Qiagen, Germany) following the 
manufacturer’s procedures and 80 µL of DNA template 
was obtained. DNA was either used immediately for a 
polymerase chain reaction (PCR) or stored at −20  °C 
for later analysis. A Nested PCR was used to analyse 
polymorphism in the merozoite surface protein msp-1 
and msp-2 genes to distinguish between recrudescence 
and new infection [10].
Sample size and data analysis
Sample size was calculated by assuming the efficacy 
of each study treatment to be at least 90  %. Under this 
assumption a sample of 155 patients per arm will be able 
to show at the 5 % significance level with 90 % power, that 
the difference in efficacy between treatments is not more 
than 10 %. Allowing for a loss to follow-up around 10 %, 
the final sample size per arm was 170 patients/year and 
then, 340 patients per arm for the 2 years. Data were dou-
ble entered by two independent data clerks and a verifica-
tion program was used to correct errors by referring to 
the original CRF. The primary treatment outcomes were 
adequate clinical and parasitological response (ACPR), 
early treatment failure (ETF), late clinical failure (LCF) 
and late parasitological failure (LPF). Total treatment 
failure (TTF) was determined as the sum of ETF, LCF 
and LPF [11]. Patients classified as treatment failures 
were given quinine (10 mg/kg orally three times a day for 
7 days) and in case of severe malaria or danger signs par-
enteral quinine was administered. Treatment secondary 
outcome measures were the tolerability of the treatment 
that was assessed by the risk of occurrence of adverse 
events (AEs).
Statistical analysis was performed using STATA (IC), 
version 10.0 software. Differences between groups were 
assessed using the Chi square test for proportions and 
analysis of variances (ANOVA) for continuous normal 
distributed variables or the non-parametric Kruskal–
Wallis to compare continuous not normally distributed 
variables. Kaplan–Meier product limit formula was used 
to estimate the risks of treatment failure and of new 
infections. A p-value of less than 0.05 was considered as 
statistically significant.
Ethics
This was part of a larger study entitled ‘Pharmacovigi-
lance for artemisinin-based combination treatments in 
Africa’ (ClinicalTrials.gov Identifier: NCT01232530). The 
study was conducted in accordance with the principle of 
good clinical practices (GCP). Before enrolment, each 
participant or parents/guardians signed informed con-
sent form. In case of illiteracy, thumb-printed consent 
was obtained in the presence of unbiased witness. The 
study was reviewed and approved by Center Muraz Insti-
tutional Ethics Committee, Burkina Faso National Ethics 
Committee and the World Health Organization (WHO) 
Ethical Review Committee.
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Results
A total of 1480 patients was screened to be included in the 
study. Among them, 1010 (68.2 %) patients were positive 
for malaria. Out of them, 680 patients were randomized to 
receive one of the two treatments. A total of 340 patients 
received ASAQ as treatment and 340 patients received 
AL. Twenty (20) patients (2.9 %) were excluded from the 
analysis and the reasons for exclusion and sampling plan 
are shown in trial profile (Fig. 1). A total of 496 (75.1 %) 
patients were children under 5  years old versus 164 
(24.8  %) over 5  years of age. The baseline characteristics 
of patients included in the study are shown in Table 1. At 
recruitment, the two treatment groups were comparable in 
all characteristics except for the haemoglobin level, which 
was higher in AL group than in ASAQ group (p = 0.019).
By day 28 the ACPR was significantly higher in ASAQ 
group than in AL group before and after adjustment 
by PCR (Table  2). Before PCR adjustment ACPR in AL 
group was 47.7 versus 67.0  % in ASAQ group [risk dif-
ference = −0.19, 95 % CI (−26.62; −11.81), p < 0.00001]. 
The adjusted ACPR was 77.8  % in AL group versus 
84.1 % in ASAQ group [risk difference = −6.32, 95 % CI 
(−12.29; −0.34), p = 0.0389]. Two ETF were found in AL 
group versus three in ASAQ treated patients.
In both AL and ASAQ groups, treatment outcomes 
were better in patients over 5 years old than in children 
under five before adjustment by PCR. Before adjust-
ment, ACPR in AL group was 43.3 and 61.7 % in children 
under 5 years and patients over 5 years old respectively 
(p  =  0.004). In ASAQ group ACPR before adjustment 
was 63.1 % in children under 5 years old versus 78.3 % in 
patients over 5 years of age (p = 0.013). After PCR adjust-
ment, ACPR was higher in older patients than in children 
less than 5 years old in both treatment groups but the dif-
ference was not statistically significant (Table 3).
The risk of recrudescence in both AL and ASAQ group 
is represented in Fig.  2. The risk of recrudescence was 
higher in AL treated patients than in those receiving 
ASAQ (p = 0.0059). In both groups the risk of recrudes-
cence became more observable after day 14.
Figure 3 represents the risk of new infection in each of 
the two treatment arms. The new infections start after 
day 14 and it was significantly higher in AL group than in 
ASAQ group.
Both AL and ASAQ treatment were well tolerated by the 
patients. An average of two AEs per patient was recorded in 
both AL and ASAQ treated patients. The most commonly 
observed AEs reported for each AL/ASAQ treatment 
Fig. 1 Trial profile. The figure shows the patients flow from the screening to the end of the follow‑up time
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Table 1 Baseline characteristics of included patients
Characteristics AL, n = 340 (%) ASAQ, n = 340 (%) P-value
Site
 Nanoro, n (%) 176 (51.76) 176 (51.76) –
 Nazoanga, n (%) 164 (48.24) 164 (48.24)
Sex
 Male, n (%) 183 (53.82) 182 (53.53) 0.939
 Female, n (%) 157 (46.18) 158 (46.47)
Age in years, median (p25–p75) 3.26 (1.70–4.98) 3.14 (1.61–5.05) 0.387
Weight in kg, median (p25–p75) 11 (9–14) 10 (9–14) 0.157
Mean temperature (SD) 38.41 (0.91) 38.47 (0.91) 0.381
Hemoglobin in g/dl, median (p25–p75) 9 (8–11) 9 (8–10) 0.019
GMPD (95 % CI) 30,529 (26,809–34,766) 30,763 (27,180–34,818) 0.933
Table 2 Primary treatment outcomes
Treatment outcome AL, n = 333 (%) ASAQ, n = 327 (%) Difference (95 % CI) P-value
PCR unadjusted
 ACPR 159 (47.8) 219 (67.0) −0.19 (−26.62; −11.81) <0.00001
 TTF 174 (52.2) 108 (43.0)
 ETF 2 (0.6) 3 (0.9)
 LCF 47 (14.1) 18 (5.5)
 LPF 125 (37.5) 87 (26.6)
PCR adjusted
 ACPR 259 (77.8) 275 (84.1) −6.32 (−12.29; −0.34) 0.0389
 TTF 74 (22.2) 52 (15.9)
 ETF 2 (0.6) 3 (0.9)
 LCF 22 (6.6) 11 (3.4)
 LPF 50 (15.0) 38 (11.6)
Table 3 Treatment outcomes by age group
Treatment Treatment outcome ≤5 years, n = 496 (%) >5 years, n = 164 (%) P-value
AL PCR unadjusted
ACPR 109 (43.3) 50 (61.7) 0.004
TTF 143 (56.7) 31 (38.3)
PCR adjusted
ACPR 192 (76.2) 67 (82.7) 0.276
TTF 60 (23.8) 14 (17.3)
ASAQ PCR unadjusted
ACPR 154 (63.1) 65 (78.3) 0.013
TTF 90 (36.9) 18 (21.7)
PCR adjusted
ACPR 199 (81.6) 76 (91.6) 0.053
TTF 45 (18.4) 7 (8.4)
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were fever (n  =  117/83) cough (n  =  75/74), diarrhoea 
(n = 61/65), rhinitis (n = 19/20), anaemia (n = 17/17),vom-
iting (n  =  11/20), abdominal pain (n  =  15/11), anorexia 
(n = 9/12), conjunctivitis (n = 6/10), otitis (n = 9/5), head-
ache (n = 7/7), and pruritus (n = 5/3). Six serious adverse 
events (SAE) were found in AL group versus four in ASAQ 
group and most of them were not linked to the treatment. 
The majority of AE was mild and was unlikely or definitely 
unrelated to the administrated treatment (Table 4).
Discussion
Although numerous studies carried out in malaria 
endemic countries had shown good efficacy and safety 
of ACT for the treatment of uncomplicated malaria, the 
conditions of clinical trials do not fully reflect real field 
situation. Moreover, the assessment of the efficacy of the 
unsupervised therapy is of greatest interest in a context of 
home management of malaria by community medicines 
distributors. This study shows that the unsupervised 
cure rate after adjustment by day 28 is 77.8 and 84.1 %, 
respectively for AL and ASAQ, indicating a lowering of 
the cure rate when drug intake is not directly supervised. 
Similar findings have been observed in a study carried 
out on Gabonese children [12]. A recent study conducted 
in the same area has also shown a cure rate of 89.7 % for 
AL and 89.8 % for ASAQ after 42 days follow-up for the 
unsupervised malaria treatment [6]. However when drug 
administration is directly supervised a cure rate of about 
90  % has always been observed [13, 14]. But as in this 
study drug intakes were not supervised and the assess-
ment adherence was based on patient self-reporting 
on day 3, this lowering of the cure rate should be taken 
with caution. This constituted one of the limitations of 
our study because some studies have shown a difference 
in adherence rate obtained by the use of different meth-
ods and the assessment based on patients self-reporting 
seems not to be the most appropriate [15, 16]. Therefore, 
compliance to the treatment and above all, the preferable 
administration of AL with fatty food that could not be 
respected in real field conditions could explain the lower-
ing of the cure rate. Thus the unsupervised therapy with 
AL results in lower plasma levels of lumefantrine with 
an increased risk for early infection [17]. Furthermore, 
vomiting was one of the commonest AEs observed in 
both AL and ASAQ treated patients. In the unsupervised 
condition it was difficult to obtain reliable information 
about time elapsed between drug intake and vomiting 
and this could affect the efficacy of the two drugs when 
Fig. 2 Kaplan–Meier survival curve of risk of recrudescence. The 
figure shows the percentage of patients with recrudescent infection 
during the 28 days follow‑up. The blue line indicates patients treated 
with artemether–lumefantrine (AL), the red line indicates patients 
treated with artesunate–amodiaquine (ASAQ)
Fig. 3 Kaplan–Meier survival curve of total risk of new infection. The 
figure shows the percentage of patients with new infection during 
the 28‑day follow‑up. The blue line indicates patients treated with 
artemether–lumefantrine (AL), the red line indicates patients treated 
with artesunate–amodiaquine (ASAQ)
Table 4 Safety information by treatment arm





Total number of adverse  
events (AE)
386 346 –
Mean AEs per patient 2 1.8 0.20
Severity of adverse events (%)
 Mild 83.4 84.7 0.642
 Moderate 13.7 13.9 0.956
 Serious 2.9 1.4 0.382
Relationship of events with the treatment (%)
 Definitely unrelated 29.5 30.3 0.810
 Unlikely 54.2 55.2 0.774
 Possible 12.7 10.7 0.401
 Probable 3.6 3.8 0.926
 Definitely related 0 0 –
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it occurred a while after drugs intake. Moreover a recent 
ex  vivo study conducted at the same area has shown a 
decrease in sensitivity of lumefantrine in the country and 
this could further explain this lowering of the cure rate 
[18]. In addition findings in a study carried out in Kenya 
indicated a decline in sensitivity of P. falciparum to ACT, 
in particular AL and dihydroartemisinin–piperaquine 
[19]. It is also known that some cases of artemisinin-
resistance have been recorded in Asia, and a particular 
care for the wide spread use at community level should 
be taken for the preservation of the activity of these drugs 
[20]. Of particular interest in this study was the involve-
ment of patients of all age groups and this shows that the 
parasitological cure rate in patients over 5 years is higher 
than for children under 5 years of age. This is not surpris-
ing and could be explained by the additive effect of the 
partially acquired immunity in aged patients living in 
endemic area due to frequent expositions to mosquito 
bites [21].
This study also shows that by day 28, over 50  % of 
treated patients had recurrent parasitaemia, most of 
them were re-infected with new P. falciparum strains. 
The risk of being re-infected is higher in AL treated 
patients than those receiving ASAQ and this starts after 
day 14 in both two study arms. The phenomenon of 
recurrent parasitaemia would increase the cost of malaria 
treatment and control and hence the use of a long half-
life medicine would be necessary in such context.
Both AL and ASAQ were well-tolerated, similar to 
many other studies with AEs mostly mild and not linked 
to the administrated treatment [5, 22]. A limitation to 
this study was the challenge of getting reliable safety 
recall information from young children who constituted 
an important part of the study population.
Conclusion
In a context where home management of malaria has 
been adopted as one of the main strategies for malaria 
control, the assessment of the effectiveness of unsuper-
vised therapy is of fundamental importance. This study 
shows a lowering of the efficacy when drug intake is not 
directly supervised. The results reported here is worrying 
as both rates are lower than the critical threshold of 90 % 
required by the WHO to recommend the use of an anti-
malarial drug in a treatment policy [23, 24]. Nevertheless, 
there is a need to conduct similar studies coupled with 
a collection of data on study participants’ adherence to 
treatment and diet habit to confirm these findings.
Abbreviations
ACT: artemisinin combination therapy; AL: artemether–lumefantrine; ASAQ: 
artesunate–amodiaquine; msp‑1: merozoite surface protein‑1 gene; msp‑2: 
merozoite surface protein‑2 gene; PCR: polymerase chain reaction; ACPR: 
adequate clinical and parasitological response; ETF: early treatment failure; 
LCF: late clinical failure; LPF: late parasitological failure; TTF: total treatment 
failure; SAE: serious adverse event; DNA: de‑oxy‑ribonucleic‑acid; GMPD: geo‑
metric mean parasite density; AE: adverse event; CRF: case record form.
Authors’ contributions
TH, SP, JBO, IV, TRG, DK, ZT, HS designed the study, TH, SP, DK, ZT, SDN, HS 
contributed for data collection and supervision in the field, SP, OZ carried out 
the laboratory analyses, AK carried out the data management and statistical 
analysis, SP, TH, ODE drafted the manuscript and all authors read and approved 
the final manuscript.
Author details
1 IRSS, Clinical Research Unit of Nanoro (CRUN), CMA Saint Camille of Nanoro, 
BP 218 Ouagadougou CMS 11, Nanoro, Burkina Faso. 2 Centre Muraz of Bobo‑
Dioulasso, Bobo‑Dioulasso, Burkina Faso. 3 Kumasi Center for Collaborative 
Research in Tropical Medicine (KCCR), Kumasi, Ghana. 
Acknowledgements
We thank the study participants and the staff of the Nanoro Health District for 
their support. We are grateful to sanofi aventis and WHO‑TDR for the financial 
support of the study. We are also grateful to the Institute of Tropical Medicine, 
Belgium (FA3‑DGCD programme) for the financial support of the laboratory 
work. Special thanks to Prof Umberto d’Alessandro and Dr Ambrose Talisuna 
for their contribution to the pharmacovigilance study protocol finalization.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interest.
Received: 6 May 2015   Accepted: 10 August 2015
References
 1. WHO. Antimalarial drug combination therapy: report of a technical 
consultation. Geneva: World Health Organization; 2001.
 2. Ministry of Health of Burkina Faso/PNLP. Directives Nationales pour la 
prise en charge du paludisme au Burkina Faso; 2006.
 3. Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H, 
et al. A randomized trial on effectiveness of artemether–lumefantrine 
versus artesunate plus amodiaquine for unsupervised treatment of 
uncomplicated Plasmodium falciparum malaria in Ghanaian children. 
Malar J. 2008;7:261.
 4. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, et al. 
Dihydroartemisinin–piperaquine and artemether–lumefantrine for 
treating uncomplicated malaria in African children: a randomised, non‑
inferiority trial. PLoS One. 2009;4:e7871.
 5. Meremikwu M, Alaribe A, Ejemot R, Oyo‑Ita A, Ekenjoku J, Nwachukwu 
C, et al. Artemether–lumefantrine versus artesunate plus amodiaquine 
for treating uncomplicated childhood malaria in Nigeria: randomized 
controlled trial. Malar J. 2006;5:43.
 6. Tinto H, Diallo S, Zongo I, Guiraud I, Valea I, Kazienga A, et al. Effective‑
ness of artesunate–amodiaquine vs. artemether–lumefantrine for the 
treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: 
a noninferiority randomised trial. Trop Med Int Health. 2014;19:469–75.
 7. Ministry of Health of Burkina Faso/DSN. Acting plan 2014 of the Nanoro 
Sanitary District; 2013.
 8. Derra K, Rouamba E, Kazienga A, Ouedraogo S, Tahita MC, Sorgho H, 
et al. Profile: Nanoro health and demographic surveillance system. Int J 
Epidemiol. 2012;41:1293–301.
 9. WHO. Toxicity grading scale for determining the severity of adverse 
events. World Health Organization; 2003.
 10. Ranford‑Cartwright L, Taylor J, Umasunthar T, Taylor L, Babiker H, Lell 
B, et al. Molecular analysis of recrudescent parasites in a Plasmodium 
falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg. 
1997;91:719–24.
Page 8 of 8Sondo et al. Malar J  (2015) 14:325 
 11. WHO. Assessment of therapeutic efficacy of antimalarial drugs for 
uncomplicated falciparum malaria. Geneva: World Health Organization; 
2003.
 12. Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, 
Salazar CO, et al. Artesunate–amodiaquine combination therapy for 
falciparum malaria in young Gabonese children. Malar J. 2007;6:29.
 13. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, et al. 
Randomized comparison of amodiaquine plus sulfadoxine–pyrimeth‑
amine, artemether–lumefantrine, and dihydroartemisinin–piperaquine 
for the treatment of uncomplicated Plasmodium falciparum malaria in 
Burkina Faso. Clin Infect Dis. 2007;45:1453–61.
 14. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, 
et al. Randomized, multicentre assessment of the efficacy and safety of 
ASAQ—a fixed‑dose artesunate–amodiaquine combination therapy in 
the treatment of uncomplicated Plasmodium falciparum malaria. Malar J. 
2009;8:125.
 15. Adams A, Soumerai SB, Lomas J, Ross‑Degnan D. Evidence of self‑
report bias in assessing adherence to guidelines. Int J Qual Health Care. 
1999;11:187–92.
 16. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, 
et al. Measurement of adherence, drug concentrations and the effective‑
ness of artemether–lumefantrine, chlorproguanil–dapsone or sulph‑
adoxine–pyrimethamine in the treatment of uncomplicated malaria in 
Malawi. Malar J. 2009;8:204.
 17. White NJ, van Vugt M, Ezzet FD. Clinical pharmacokinetics and 
pharmacodynamics of artemether–lumefantrine. Clin Pharmacokinet. 
1999;37:105–25.
 18. Tinto H, Bonkian LN, Nana LA, Yerbanga I, Lingani M, Kazienga A, et al. Ex 
vivo anti‑malarial drugs sensitivity profile of Plasmodium falciparum field 
isolates from Burkina Faso five years after the national policy change. 
Malar J. 2014;13:207.
 19. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. 
Declining responsiveness of Plasmodium falciparum infections to 
artemisinin‑based combination treatments on the Kenyan coast. PLoS 
One. 2011;6:e26005.
 20. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. 
Emergence of artemisinin‑resistant malaria on the western border of 
Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
 21. Ladeia‑Andrade S, Ferreira MU, de Carvalho ME, Curado I, Coura JR. 
Age‑dependent acquisition of protective immunity to malaria in 
riverine populations of the Amazon Basin of Brazil. Am J Trop Med Hyg. 
2009;80:452–9.
 22. Brasseur P, Vaillant MT, Olliaro PL. Anti‑malarial drug safety information 
obtained through routine monitoring in a rural district of South‑Western 
Senegal. Malar J. 2012;11:402.
 23. WHO. Guidelines for the treatment of malaria. Geneva: World Health 
Organization; 2010.
 24. WHO. Global report on antimalaria drug efficacy and drug resistance: 
2000–2010. Geneva: World Health Organization; 2000.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
